L. Down

发表

Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array

J. R. Wilson, David M. Holden, P. W. Foster, 2016, British Journal of Cancer.

Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial

L. Holmberg, J. Oxley, J. Sterne, 2016, Trials.

Patient‐reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life

Joyce E. Wilkinson, T. Peters, P. Fayers, 2016, BJU international.

A Peer Review Intervention for Monitoring and Evaluating sites (PRIME) that improved randomized controlled trial conduct and performance.

F. Hamdy, D. Neal, J. Donovan, 2011, Journal of clinical epidemiology.

ProDiet: A Phase II Randomized Placebo-controlled Trial of Green Tea Catechins and Lycopene in Men at Increased Risk of Prostate Cancer

F. Hamdy, D. Neal, J. Donovan, 2018, Cancer Prevention Research.

Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)

Richard M Martin, Freddie C Hamdy, Julia Verne, 2016, BMJ Open.

Patient‐reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life

Joyce E. Wilkinson, T. Peters, P. Fayers, 2016, BJU international.

Men with prostate cancer make positive dietary changes following diagnosis and treatment

F. Hamdy, D. Neal, J. Donovan, 2013, Cancer Causes & Control.

Associations of aspirin, nonsteroidal anti‐inflammatory drug and paracetamol use with PSA‐detected prostate cancer: Findings from a large, population‐based, case–control study (the ProtecT study)

F. Hamdy, D. Neal, J. Donovan, 2011, International journal of cancer.

Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial.

T. Peters, F. Hamdy, D. Neal, 2014, The Lancet. Oncology.

Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)

J. Sterne, F. Hamdy, D. Neal, 2014, British Journal of Cancer.

Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee

J. Oxley, J. Sterne, F. Hamdy, 2016, British Journal of Cancer.

Factors distinguishing general practitioners who more readily participated in a large randomized trial were identified.

F. Hamdy, D. Neal, J. Donovan, 2009, Journal of clinical epidemiology.

Ethnic differences in prostate-specific antigen levels in men without prostate cancer: a systematic review

T. Martins, J. Watson, S. Merriel, 2022, Prostate Cancer and Prostatic Diseases.

Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial

F. Hamdy, D. Neal, J. Donovan, 2007, BMJ : British Medical Journal.

Psychological distress and prostate specific antigen levels in men with and without prostate cancer

F. Hamdy, D. Neal, J. Donovan, 2009, Brain, Behavior, and Immunity.

Seasonal variation in prostate‐specific antigen levels: a large cross‐sectional study of men in the UK

F. Hamdy, J. Donovan, C. Metcalfe, 2011, BJU international.

Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result

F. Hamdy, D. Neal, J. Donovan, 2010, British Journal of Cancer.

Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy?

F. Hamdy, D. Neal, J. Donovan, 2009, European journal of cancer.

Associations of aspirin, nonsteroidal anti‐inflammatory drug and paracetamol use with PSA‐detected prostate cancer: Findings from a large, population‐based, case–control study (the ProtecT study)

F. Hamdy, D. Neal, J. Donovan, 2011, International journal of cancer.